About Nuclear pore complex protein Nup88
Nuclear pore complex protein Nup88 (NUP88) is a protein
from Homo sapiens identified by UniProt accession
Q99567, 741 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Nuclear pore complex protein Nup88 |
|---|
| UniProt accession | Q99567 |
|---|
| Gene | NUP88 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 741 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99567-F1 | alphafold | PREDICTED | 79.41 | — |
Amino-acid sequence (741 residues)
MAAAEGPVGD GELWQTWLPN HVVFLRLREG LKNQSPTEAE KPASSSLPSS PPPQLLTRNV VFGLGGELFL WDGEDSSFLV VRLRGPSGGG EEPALSQYQR LLCINPPLFE IYQVLLSPTQ HHVALIGIKG LMVLELPKRW GKNSEFEGGK STVNCSTTPV AERFFTSSTS LTLKHAAWYP SEILDPHVVL LTSDNVIRIY SLREPQTPTN VIILSEAEEE SLVLNKGRAY TASLGETAVA FDFGPLAAVP KTLFGQNGKD EVVAYPLYIL YENGETFLTY ISLLHSPGNI GKLLGPLPMH PAAEDNYGYD ACAVLCLPCV PNILVIATES GMLYHCVVLE GEEEDDHTSE KSWDSRIDLI PSLYVFECVE LELALKLASG EDDPFDSDFS CPVKLHRDPK CPSRYHCTHE AGVHSVGLTW IHKLHKFLGS DEEDKDSLQE LSTEQKCFVE HILCTKPLPC RQPAPIRGFW IVPDILGPTM ICITSTYECL IWPLLSTVHP ASPPLLCTRE DVEVAESPLR VLAETPDSFE KHIRSILQRS VANPAFLKAS EKDIAPPPEE CLQLLSRATQ VFREQYILKQ DLAKEEIQRR VKLLCDQKKK QLEDLSYCRE ERKSLREMAE RLADKYEEAK EKQEDIMNRM KKLLHSFHSE LPVLSDSERD MKKELQLIPD QLRHLGNAIK QVTMKKDYQQ QKMEKVLSLP KPTIILSAYQ RKCIQSILKE EGEHIREMVK QINDIRNHVN F
Explore Nuclear pore complex protein Nup88 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets